Korro Bio files first regulatory submission for KRRO-110 in AATD, expects first dosing Q1 2025

Korro Bio, Inc.

Regulatory filing submitted to Australian Bellberry HREC for Phase 1/2 study of KRRO-110 in Alpha-1 Antitrypsin Deficiency.
First participant dosing anticipated in Q1 2025; interim readout expected H2 2025; study completion in 2026.
Formed Clinical Advisory Board of six lung and liver experts to guide development strategy.
KRRO-110 is first RNA editing oligonucleotide from Korro's OPERA platform, targeting SERPINA1 RNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.